Fighting the invisible foe in cancer therapy

Di Ran; Jun Sun

doi:10.1016/j.chom.2024.07.016

Fighting the invisible foe in cancer therapy

Cell Host Microbe. 2024 Aug 14;32(8):1214-1216. doi: 10.1016/j.chom.2024.07.016.

Authors

Di Ran¹, Jun Sun²

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA.
² Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois Chicago, Chicago, IL, USA; UIC cancer Center, University of Illinois Chicago, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: junsun7@uic.edu.

PMID: 39146791
DOI: 10.1016/j.chom.2024.07.016

Abstract

In this issue of Cell Host & Microbe, Huang et al. determine that an oncogenic bacterium contributes to colorectal cancer progression and resistance to receptor tyrosine kinase inhibitors. These findings highlight the need for an integrative approach for cancer treatment that considers the influence of the microbiome.

MeSH terms

Animals
Colorectal Neoplasms* / drug therapy
Drug Resistance, Neoplasm
Gastrointestinal Microbiome / drug effects
Humans
Microbiota / drug effects
Neoplasms / drug therapy
Neoplasms / therapy
Protein Kinase Inhibitors / therapeutic use

Substances

Protein Kinase Inhibitors